LONDON (Reuters) - A warning from U.S. regulators linking GlaxoSmithKline’s diabetes drug Avandia to rare cases of swelling in the back of the eye is unlikely to have a major impact on sales, analysts said on Friday. The Food and Drug Administration highlighted the problem in a notice late on Thursday after the drug maker said it had received “very rare” reports of the swelling, known as macular oedema, in patients taking Avandia.
